Pfizer Deferred Tax Assets decreased by 100.5% to -$12.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 100.5%, from $2.26B to -$12.00M. Over 5 years (FY 2020 to FY 2025), Deferred Tax Assets shows a downward trend with a -10.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase can signal future tax efficiency or the utilization of past losses, while a decrease may indicate the realization of those benefits.
These are assets on the balance sheet that represent future tax savings resulting from temporary differences between the...
Common in large, capital-intensive companies; peers with significant R&D spending often have large deferred tax assets from tax credits.
deferred_tax_assets| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.16B | $328.00M | $349.00M | $655.00M | $558.00M | $616.00M | $1.02B | $1.07B | $1.23B | $1.13B | $640.00M | $931.00M | $2.23B | $2.16B | $2.12B | $2.26B | $2.48B | $2.47B | $2.40B | -$12.00M |
| QoQ Change | — | -92.1% | +6.4% | +87.7% | -14.8% | +10.4% | +66.1% | +4.3% | +15.5% | -8.7% | -43.1% | +45.5% | +139.2% | -3.1% | -1.7% | +6.4% | +9.9% | -0.6% | -2.7% | -100.5% |
| YoY Change | — | — | — | — | -86.6% | +87.8% | +193.1% | +62.9% | +120.8% | +82.6% | -37.4% | -12.7% | +80.8% | +91.8% | +231.6% | +142.5% | +11.4% | +14.3% | +13.1% | -100.5% |